Tweets
AAD 2026 Annual Mtg presents new data on another TYK2 inhibitor. In 2 phase 3 RCTs (ONWARD1 ONWARD2) envudeucitinib was superior to placebo & apremilast in 1700 plaque psoriasis pts https://t.co/DPlzDw5m7N
Dr. John Cush @RheumNow ( View Tweet )
3 hours 12 minutes ago
What's it like to have #RA? PATTY "To find patients or doctors who can talk intelligently about RA is a welcomed relief. However, I prefer that those around me not know about me and my RA. I hope they don’t notice the changes in my hands or shoes or that I cannot wear my usual https://t.co/OQbXJrcyPp
Dr. John Cush @RheumNow ( View Tweet )
6 hours 33 minutes ago
After hours EHR catchup has been coined "Pajama time" by residents & physicians & contributes to burnout. Survey 9,731 YR 2 Family Med residents- spend 3+ hrs/d after wk on ambulatory EHRs. Pajama time assoc w/ less knowledge, professional satisfaction, more burnout. https://t.co/QSR7VM2T7u
Dr. John Cush @RheumNow ( View Tweet )
1 day ago
Brepocitinib in Dermatomyositis
The NEJM reports that brepocitinib, an oral TYK2–JAK1 inhibitor, was studied in a phase 3 trial of refractory dermatomyositis (DM) patients and shown to have significant benefits at the higher dose.
https://t.co/YNxrVTIubb https://t.co/uFY3kMOvui
Dr. John Cush @RheumNow ( View Tweet )
1 day ago
AFFINITY Study - Combination Biologic Therapy in PsA
A pilot trial assessed the efficacy and safety of the guselkumab+golimumab (COMBO) combination versus GUS monotherapy in active PsA (failing a prior tumor necrosis factor inhibitor (TNFi-IR) and showed superiority in ACR 50 https://t.co/f2CB8FnZMB
Dr. John Cush @RheumNow ( View Tweet )
1 day 5 hours ago
FDA has issued a drug safety warning for avacopan (Tavneos), dentifying 76 cases of drug-induced liver injury, including 7 cases of rare vanishing bile duct syndrome (VBDS). There were 8 deaths https://t.co/WkBhs1rNpf https://t.co/ZXdHsAJUOQ
Dr. John Cush @RheumNow ( View Tweet )
1 day 6 hours ago
The Mucosal Hypothesis of Rheumatoid Arthritis. Dr. Kristin Demoruelle
In this https://t.co/4UQlqwujiR 2026 podcast, Dr. Kristin Demoruelle explores the mucosal origins of RA and its implications.
🎧 Listen here: https://t.co/QxldIpYQC8
#Rheumatology #Autoimmunity #RNL2026 https://t.co/nz2dbwll14
Dr. John Cush @RheumNow ( View Tweet )
1 day 7 hours ago
DERM on RheumNow PODCAST (March 2026)
https://t.co/OGl34cH6z5 https://t.co/l7v1Xktl8r
Dr. John Cush @RheumNow ( View Tweet )
1 day 10 hours ago
Moral Distress (3.27.2026)
Dr. Jack Cush reviews the journal reports and news from RheumNow. This week we discuss moral distress, FM in PsA, Lyme Vax is back & hidden but tangible benefits of the MDHAQ.
https://t.co/LdNcsUcHc2 https://t.co/tRYeDhQ3hC
Dr. John Cush @RheumNow ( View Tweet )
2 days ago
AXIS is an Intl prospective study of 409 psoriatic arthritis pts - found Axial involvement in 27.4% of pts. Axial PsA signif younger (45 vs 47.6 yrs) , male (56% vs 51.5%), more B27 positivity (22% vs 11%), inflammatory back pain (75% vs 43%), & ^CRP (53% vs 37%) https://t.co/XY5pf4BNNm
Dr. John Cush @RheumNow ( View Tweet )
2 days 5 hours ago
19 yr old male is Dx w/ Stills Dz (Fever 104F, pleuritis, organomegaly, WBC 24k, ESR 98, CRP 11 mg/L) - what drug do you prescribe first?
Dr. John Cush @RheumNow ( View Tweet )
2 days 7 hours ago
Portugese multicentre retrospective of 748 adults with JIA (age 28 yrs; Dz duration 21 yrs). Oligoarticular JIA was the most common subtype (29.9%). HTN (9%), psychiatric dz (8%), & osteoporosis (5%) were most prevalent comorbidities. bDMARD use reduced risk of psych Dz https://t.co/xCrTDxirlj
Dr. John Cush @RheumNow ( View Tweet )
2 days 7 hours ago


